Getting Started with Carolina Complete Health

This guide provides need-to-know information regarding the provider portal, securing prior authorizations, important phone numbers, and more!

Known Issues Tracker

This document provides timely information related to known issues impacting providers. This will be updated weekly on Thursdays. 

Provider Announcements

The NC Department of Health and Human Services is committed to ensuring providers have timely and relevant information about the monkeypox outbreak and the response efforts in North Carolina.

To support these efforts, NC AHEC is partnering with NCDHHS to host Monkeypox Update for Providers, a live webinar to update providers on the issue. The webinar will be held on Thursday, Sept. 8, from 6 – 7:15 p.m.

 

Registration is available at this link: us06web.zoom.us/webinar/register/WN_mNZ3WGB9TjChonZ3xTU5dg

 

  • More specific guidance on genetic testing has been adopted for several areas of genetic evaluation; please see the following for current guidance.
    • Adoption of the following Genetic Testing Clinical Coverage Policies (CP.MP.227, CP.MP.217, CP.MP.218, CP.MP.219, CP.MP.220, CP.MP.224, CP.MP. 226, CP.MP.228, CP.MP.229, CP.MP.230, CP.MP.236, CP.MP.237, CP.MP.238, CP.MP.239, CP.MP.240, CP.MP.241, CP.MP.215, CP.MP.216, CP.MP.221, CP.MP.222, CP.MP.223, CP.MP.225, CP.MP.231, CP.MP.232, CP.MP.233, CP.MP.234, CP.MP.235)

 

 

  • Carolina Complete Health has attested to the use of the following policies:​
    • Revised policy NC.CP.MP.117Spinal Cord, Peripheral Nerve, and Percutaneous Electrical Nerve Stimulation ​
    • CP.MP.40 Gastric Electrical Nerve Stimulation
    • CP.MP.203 Diaphragmatic Phrenic Nerve Stimulation​
    • Revised Policy CP.MP.146: Sclerotherapy and Chemical Endovenous Ablation for Varicose Veins​
      • The following codes were added in the list of codes that support medical necessity: 36482 & 36483​
    • More specific guidance on genetic testing has been adopted for several areas of genetic evaluation; please see the following for current guidance. We anticipate further guidance on several other genetic topics in the coming months.​
      • Adoption of the following Genetic Testing Clinical Coverage Policies (CP.MP.227, CP.MP.217, CP.MP.218, CP.MP.219, CP.MP.220, CP.MP.224, CP.MP. 226, CP.MP.228, CP.MP.229, CP.MP.230, CP.MP.236, CP.MP.237, CP.MP.238, CP.MP.239, CP.MP.240, CP.MP.241)​